Evelo Competitors

Delisted . USA . 
Stock . Evelo Biosciences
EVLODelisted Stock  USD 8.23  2.68  24.56%   
Evelo Biosciences competes with Aileron Therapeutics, ABVC Biopharma, Surrozen, Processa Pharmaceuticals, and Tempest Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Evelo Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Evelo Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Evelo Biosciences competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
8.238.238.23
Details
Intrinsic
Valuation
LowRealHigh
6.326.329.05
Details
Naive
Forecast
LowNextHigh
11.4511.4511.45
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.733.848.42
Details

Evelo Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Evelo Biosciences and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Evelo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Evelo Biosciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CTMX
+ 0.83
TPST
CTMX
+ 0.8
PCSA
TPST
+ 0.73
PCSA
TPST
+ 0.68
NEXI
NEXI
+ 0.66
PCSA
CTMX
+ 0.63
NEXI
  
High negative correlations   
ALRN
- 0.64
APTX
PCSA
- 0.5
MGTA
NEXI
- 0.49
ALRN
CTMX
- 0.49
MGTA
TPST
- 0.44
ALRN
TPST
- 0.39
MGTA

Risk-Adjusted Indicators

There is a big difference between Evelo Pink Sheet performing well and Evelo Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Evelo Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
APTX  7.26 (2.50) 0.00 (0.48) 0.00 
 0.00 
 12.50 
(16.67)
 75.72 
MGTA  2.62  0.13  0.00 (0.71) 3.40 
(3.33)
 5.88 
(4.29)
 16.99 
ALRN  4.26  0.15  0.01  0.78  4.81 
(5.03)
 8.06 
(7.99)
 41.47 
ABVC  3.71 (0.24) 0.00  0.58  0.00 
 0.00 
 7.25 
(9.09)
 35.84 
SRZN  5.02  0.63  0.09 (0.84) 4.90 
(6.27)
 16.74 
(7.91)
 33.59 
PCSA  2.47 (0.87) 0.00 (0.85) 0.00 
 0.00 
 6.06 
(5.34)
 20.99 
NEXI  4.85 (0.36) 0.00 (0.72) 0.00 
 0.00 
 5.90 
(9.00)
 94.30 
TPST  3.86 (0.75) 0.00 (0.59) 0.00 
 0.00 
 6.38 
(8.53)
 29.55 
NLTX  2.25 (0.19) 0.00 (1.83) 0.00 
 0.00 
 4.05 
(3.53)
 27.84 
CTMX  2.62 (0.64) 0.00 (0.45) 0.00 
 0.00 
 5.00 
(5.49)
 20.61 
All Fundamental Data

Evelo Biosciences Competitive Analysis

The better you understand Evelo Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Evelo Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Evelo Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EVLO APTX MGTA ALRN ABVC SRZN PCSA NEXI TPST NLTX
 24.56 
 8.23 
Evelo
 16.67 
 0.07 
Aptinyx
 3.80 
 0.82 
Magenta
 4.26 
 2.47 
Aileron
 3.51 
 0.55 
ABVC
 1.61 
 9.15 
Surrozen
 2.27 
 0.86 
Processa
 9.95 
 2.43 
Neximmune
 2.25 
 0.91 
Tempest
 1.43 
 0.69 
Neoleukin
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Dangerous
Out of control
Risky
Dangerous
Very steady
Relatively risky
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Dangerous
About Average
Very High
Very High
Very High
Dangerous
Very High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Hold
Buy
Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Not Rated
Current Ratio
4.53
16.22
10.22
6.51
2.68
11.12
8.89
6.54
3.05
12.78
Net Asset
64.44 M
66.68 M
146.65 M
106.01 M
14.49 M
46.08 M
5.79 M
8.59 M
51.6 M
115.95 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(108.41 M)
(62.57 M)
(78.98 M)
(15.61 M)
(8.13 M)
(41.13 M)
(11.46 M)
(28.17 M)
(28.78 M)
(56.48 M)
Current Valuation
23.69 M
(25.91 M)
(32.66 M)
38.63 M
9.07 M
738.12 K
(2.48 M)
(491.95 K)
34.62 M
(35.02 M)
Price To Book
3.51
0.33
0.54
1.11
0.83
5.33
0.49
1.38
3.4
0.44
Operating Margin
N/A
N/A
N/A
N/A
-8.34
0.12
N/A
N/A
N/A
N/A
Retained Earnings
(529.22 M)
(352.74 M)
(402.03 M)
(288.52 M)
(65.42 M)
(221.69 M)
(75.37 M)
(222.59 M)
(165.26 M)
(451.06 M)
Current Asset
49.29 M
59.11 M
33.34 M
3.43 M
N/A
N/A
N/A
N/A
N/A
289 K
Beta
1.74
1.33
2.12
2.34
0.82
0.94
0.6
1.94
-2.78
1.1
Number Of Employees
66
12
67
15
16
42
13
6
17
7
Shares Outstanding
18.93 M
67.72 M
60.66 M
21.67 M
12.24 M
3.25 M
3.27 M
1.37 M
43.64 M
2.35 M
Cash Flow From Operations
(101.23 M)
(59.68 M)
(67.09 M)
(19.81 M)
(4.24 M)
(40.36 M)
(8.06 M)
(31.43 M)
(27.36 M)
(45.61 M)
Total Debt
51.14 M
22.11 M
29.96 M
48 K
2.28 M
3.38 M
150.55 K
68.81 K
20.66 M
12.07 M
Return On Equity
-62.33
-1.38
-0.65
-0.44
-3.2
-1.74
-2.12
-1.96
-2.89
-0.38
Z Score
-16.24
-9.34
-3.88
N/A
N/A
N/A
N/A
N/A
N/A
-5.73
Return On Asset
-0.83
-0.51
-0.29
-0.26
-0.45
-0.33
-1.13
-0.7
-0.54
-0.19
Number Of Shares Shorted
430.1 K
2.23 M
383.03 K
233.27 K
186.19 K
34.89 K
97.4 K
15.99 K
2.64 M
26.4 K
Book Value Per Share
-1.42
0.27
1.24
1.41
1.06
1.76
1.14
2.0
1.21
34.18
Current Liabilities
4.32 M
4.69 M
3.39 M
459 K
N/A
N/A
N/A
N/A
N/A
1.02 M
Total Asset
64.44 M
66.68 M
146.65 M
106.01 M
14.49 M
46.08 M
5.79 M
8.59 M
51.6 M
115.95 M
Debt To Equity
1.55
0.39
0.25
0.003
0.34
0.073
0.001
0.023
0.49
0.11
Short Ratio
0.42
1.13
1.38
3.47
0.7
1.32
0.71
2.26
0.39
1.7
Target Price
10.0
0.5
1.0
13.0
2.02
33.0
6.0
2.0
18.75
1.5
Shares Owned By Institutions
83.13
42.96
62.63
28.47
3.01
77.18
1.48
11.17
23.02
45.58
Market Capitalization
7 M
4.57 M
45.14 M
55.9 M
6.73 M
30.22 M
2.87 M
3.25 M
39 M
8.2 M
Price To Earning
-4.19
-5.61
-1.63
-0.31
N/A
N/A
N/A
N/A
0.23
-4.6
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
-0.05
-0.12
N/A
N/A
-0.03
Price To Sales
N/A
45.33
N/A
N/A
49.37
3.02
N/A
N/A
N/A
N/A
Net Income
(114.53 M)
(64.85 M)
(76.46 M)
(15.73 M)
(10.52 M)
(43.04 M)
(11.12 M)
(32.34 M)
(29.49 M)
(57.56 M)
Earnings Per Share
-15.64
-0.65
-1.11
-2.88
-0.81
-16.94
-5.25
-24.11
-1.53
-12.28
Shares Owned By Insiders
0.23
13.12
2.23
0.6
22.92
1.6
8.74
17.0
0.24
16.46
Revenue
N/A
N/A
N/A
N/A
152.43 K
12.5 M
N/A
N/A
N/A
N/A
Working Capital
39.18 M
57.74 M
101.05 M
13.88 M
(4.28 M)
33.98 M
4.9 M
316.73 K
30.95 M
88.07 M
Cash And Equivalents
92.01 M
85.27 M
128.28 M
32.38 M
2.99 M
92.69 M
12.06 M
53.13 M
51.62 M
116.46 M
Cash Per Share
0.85
1.26
2.13
0.36
0.09
2.64
0.76
2.2
4.95
2.73
Gross Profit
N/A
(54.44 M)
N/A
(17.01 M)
350.71 K
N/A
N/A
N/A
N/A
N/A
Day Typical Price
9.09
0.0633
0.81
2.5
0.55
9.28
0.88
2.39
0.9
0.69
Accumulation Distribution
0.26
0.29
0.0482
12549.81
3407.02
1072.54
3038.8
0.17
48012.13
0.0563
Market Facilitation Index
2.85
0.02
0.04
0.0
0.0
1.0E-4
0.0
0.44
N/A
0.04
Daily Balance Of Power
(0.94)
0.5
0.75
(0.31)
(0.50)
(0.13)
(0.25)
0.5
0.3333
(0.25)
Period Momentum Indicator
(2.68)
0.01
0.03
(0.11)
(0.02)
(0.15)
(0.02)
0.22
0.02
(0.01)
Rate Of Daily Change
0.75
1.17
1.04
0.96
0.96
0.98
0.98
1.1
1.02
0.99
Day Median Price
9.52
0.06
0.81
2.51
0.55
9.35
0.89
2.37
0.9
0.69
Price Action Indicator
(2.63)
0.015
0.025
(0.1)
(0.01)
(0.27)
(0.04)
0.17
0.02
(0.01)
Coefficient Of Variation
675.8
(607.06)
2966.12
3299.03
(2,091)
1180.41
(455.87)
(3,356)
(803.57)
(2,179)
Mean Deviation
14.3
7.26
2.62
4.26
3.71
5.02
2.47
4.85
3.86
2.25
Jensen Alpha
3.5
(2.50)
0.1305
0.1508
(0.24)
0.6293
(0.87)
(0.36)
(0.75)
(0.19)
Total Risk Alpha
0.3733
(3.71)
(0.37)
(0.61)
(1.03)
(0.32)
(1.24)
(1.66)
(1.31)
(0.66)
Sortino Ratio
0.2391
N/A
0.0036
0.0145
N/A
0.0908
N/A
N/A
N/A
N/A
Downside Variance
170.5
N/A
17.78
25.45
N/A
26.0
N/A
N/A
N/A
N/A
Standard Deviation
21.84
12.54
3.69
6.03
5.73
6.76
3.52
10.32
5.1
3.7
Kurtosis
6.07
11.31
3.46
6.13
7.52
1.53
2.11
34.29
1.66
13.95
Potential Upside
46.25
12.5
5.88
8.06
7.25
16.74
6.06
5.9
6.38
4.05
Treynor Ratio
(1.17)
(0.48)
(0.71)
0.7801
0.5782
(0.84)
(0.85)
(0.72)
(0.59)
(1.83)
Maximum Drawdown
131.59
75.72
16.99
41.47
35.84
33.59
20.99
94.3
29.55
27.84
Variance
477.0
157.18
13.63
36.39
32.89
45.68
12.4
106.45
26.04
13.69
Market Risk Adjusted Performance
(1.16)
(0.47)
(0.70)
0.7901
0.5882
(0.83)
(0.84)
(0.71)
(0.58)
(1.82)
Risk Adjusted Performance
0.1225
(0.12)
0.0336
0.0319
(0.03)
0.0735
(0.16)
(0.01)
(0.09)
(0.03)
Skewness
1.96
(2.42)
(0.42)
1.44
1.77
1.03
(0.28)
4.71
(0.64)
(2.77)
Semi Deviation
11.93
N/A
3.4
4.81
N/A
4.9
N/A
N/A
N/A
N/A
Information Ratio
0.143
(0.17)
0.0041
0.0122
(0.07)
0.0685
(0.25)
(0.04)
(0.15)
(0.08)
Value At Risk
(26.62)
(16.67)
(4.29)
(7.99)
(9.09)
(7.91)
(5.34)
(9.00)
(8.53)
(3.53)
Expected Short fall
(19.79)
N/A
(3.33)
(5.03)
N/A
(6.27)
N/A
N/A
N/A
N/A
Downside Deviation
13.06
N/A
4.22
5.05
N/A
5.1
N/A
N/A
N/A
N/A
Semi Variance
142.43
N/A
11.57
23.14
N/A
24.01
N/A
N/A
N/A
N/A

Evelo Biosciences Competition Performance Charts

Five steps to successful analysis of Evelo Biosciences Competition

Evelo Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Evelo Biosciences in relation to its competition. Evelo Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Evelo Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Evelo Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Evelo Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Evelo Biosciences position

In addition to having Evelo Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Fabricated Products Thematic Idea Now

Fabricated Products
Fabricated Products Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Evelo Pink Sheet

If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY